<DOC>
	<DOC>NCT02091986</DOC>
	<brief_summary>The purpose is to investigate the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared with Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in Children Ages 6 to &lt;12 Years with Asthma during 12 weeks.</brief_summary>
	<brief_title>A 12-Week Study in Asthmatic Children Ages 6 to &lt;12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg</brief_title>
	<detailed_description>A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg, 2 Actuations Twice Daily, and Symbicort pMDI 80/4.5 μg, 2 Actuations Twice Daily, Compared with Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in Children Ages 6 to &lt;12 Years with Asthma</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Has a documented clinical diagnosis of asthma defined by the ATS for at least 6 months prior to Visit 2 Have a morning prebronchodilator clinic FEV1 measured at least 6 hours after the last dose of inhaled SABA and at least 48 hours after last dose of inhaled LABA of 60% to 100% of predicted normal Demonstrated reversibility of clinic FEV1 of ≥12% from pre albuterol/salbutamol level within 15 to 30 minutes after administration of a standard dose of albuterol/salbutamol. Have been hospitalized at least once or required emergency treatment more than once for an asthmarelated condition during the 6 months prior to Visit 1 Have required treatment with systemic corticosteroids (eg, oral, parenteral, or rectal) for any reason within the 6 weeks prior to Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>asthma, children, budesonide pMDI</keyword>
</DOC>